IRCT20200705048005N1已完成未知
Single-dose bioequivalence studies of two febuxostat tablets in healthy volunteers
ChemiDaru Pharmaceutical Company0 个研究点目标入组 26 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 50 years（—）
- 性别
- Male
入选标准
- •Male volunteer
- •Age: 18-50 year
- •Healthyvolunteer
排除标准
- •History of liver, kidney and cardiovascular diseases that can affect drug clearance from body
- •Any medication prescribed in the last two weeks
研究者
相似试验
已完成
1 期
A Bioequivalence study of single dose, two-way crossover design with two-period, two-treatment of Octreotide-SBS 100 mcg/mL subcutaneous injection relative to Sandostatin®Healthy VolunteersTCTR20180920004Siam Bioscience28
尚未招募
1 期
Single-Dose, Fed Bioequivalence study of Mylan Esomeprazole 40 mg DR tablets; Mylan Laboratories Limited, India relative to Nexium® 40 mg tablets of AstraZeneca in healthy Thai volunteersBioequivalence studyEsomeprazoleTCTR20200630001Bio-innova and Synchron.Co.,Ltd48
尚未招募
1 期
Single-Dose, Fed Bioequivalence Study of MYLAN Rivaroxaban Tablets 20 mg (20 mg; Mylan) and Xarelto® 20 mg (20 mg; Bayer) in Healthy Adult VolunteersBioequivalence Study,Healthy,Thai VolunteersRivaroxaban ,TCTR20201224002International Bio Service Co.,Ltd.36
尚未招募
不适用
Bioequivalence Study of Dolutegravir Sodium Dispersible Tablet 10 mg (Fed)CTRI/2019/06/019953Macleods Pharmaceuticals Ltd
Unknown
1 期
A Bioequivalence study of a randomized, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Linagliptin Film Coated Tablets 5 mg relative to Trajenta 5 mg film-coated tablets in healthy Thai adult volunteers under fasting conditioHealthy subjectsBioequivalence (Linagliptin) 5 mgTCTR20221212003Mylan Laboratories Limited.36